Milind Deshpande, PhD

Venture Partner

Milind Deshpande is a Venture Partner at Raven. Milind is also the co-founder and Chairman of the Board of Directors of Spero Therapeutics and Scientific Advisory Board member at Avilar Therapeutics. Prior to Raven, Milind was the CEO at Hyku Biosciences and President and CEO of Nayan Therapeutics and Hyku Biosciences, both were RA Capital portfolio companies. Prior to that, Milind was the President, CEO and member of the Board of Directors of Achillion Pharmaceuticals, and was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Milind is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Milind was a Fellow and Instructor in the Department of Medicine, Boston University School of Medicine. Milind attended the residential Executive Program at The Wharton School of Management. Milind holds a PhD in Organic Chemistry from Ohio University.